Clinical Study

Serum Fatty Acids and Risk of Cutaneous Melanoma: A Population-Based Case-Control Study

Table 3

Odds ratio (OR) with 95% confidence intervals (CI) of melanoma by tertile of serum fatty acid percentage composition.

IaIIIII trend
OROR(95% CI)OR(95% CI)

SFAsb
 Palmitic1.001.00(0.37–2.71)0.75(0.23–2.41)0.568
 Margaric (daturic)1.000.85(0.30–2.47)1.29(0.40–4.21)0.783
 Stearic1.001.48(0.50–4.42)1.94(0.61–6.20)0.115
 Arachidic1.001.76(0.44–7.02)2.13(0.61–7.46)0.400
 Lignoceric1.000.69(0.24–1.99)0.57(0.18–1.77)0.725
MUFAsb
 Oleic1.001.02(0.42–2.46)1.23(0.44–3.45)0.909
 Nervonic1.001.79(0.51–6.24)1.59(0.32–7.94)0.876
PUFAsb
 Linoleic1.000.73(0.27–1.98)0.77(0.28–2.15)0.406
 Arachidonic1.000.57(0.21–1.55)1.33(0.53–3.33)0.402
 EPA1.002.17(0.68–6.90)1.16(0.30–4.43)0.600
 DPA1.001.2(0.44–3.24)1.00(0.34–2.91)1.000
 DHA1.000.65(0.22–1.90)0.67(0.24–1.86)0.891
Groupings
 SFAs1.000.41(0.11–1.48)1.65(0.49–5.51)0.589
 MUFAs + PUFAs1.000.81(0.31–2.16)0.76(0.23–2.55)0.884
 MUFAs1.000.95(0.35–2.59)1.08(0.36–3.24)0.932
 PUFAs1.000.57(0.20–1.64)0.78(0.27–2.21)0.859
 SFAs/MUFAs + PUFAs1.001.03(0.33–3.25)1.25(0.41–3.81)0.907
 SFAs/PUFAs1.000.71(0.26–1.95)1.33(0.50–3.46)0.478
 n-3 PUFAs1.000.82(0.24–2.71)1.11(0.37–3.36)0.718
 n-6 PUFAs1.000.61(0.21–1.74)0.90(0.33–2.47)0.807
 n-3 PUFAs/n-6 PUFAs1.001.99(0.73–5.26)1.31(0.42–4.02)0.679

aReferent group.
bSFAs: saturated fatty acids; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids.